Analystreport

Royalty Pharma PLC (NASDAQ: RPRX) was given a new $54.00 price target on by analysts at Morgan Stanley.

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations